Pivot Pharmaceuticals Inc. PVOTF Archives - Page 2 of 4

FridayJun 15, 2018 3:04 pm

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Leveraging Proprietary Technology in Innovative Cannabinoid Product Pipeline

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is leveraging innovative technology to target pain and a number of chronic conditions. A recent article discussing this reads, “These proprietary technologies are deployed in the development of cannabidiol (CBD) and tetrahydrocannabinol (THC) based products. Pivot’s cannabinoid pipeline of pharmaceutical products includes two that use the Solmic drug delivery technology for cancer supportive care, targeting the relief of mucositis and chemotherapy-induced nausea and vomiting. The company has also deployed its Bi-Phasix™ delivery platform for the development of four products that target women’s sexual desire disorder, glaucoma, dysmenorrhea and dermatological conditions. Pivot’s…

FridayJun 08, 2018 11:03 am

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc.’s (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Advanced Technologies Drive Product Development

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) is an emergent biopharmaceutical company engaged in the development and commercialization of pharmaceuticals and nutraceuticals that deliver innovative treatments for unmet healthcare needs. An article discussing the company reads: “The advent of modern licensing controls for over-the-counter medications in Canada nearly 15 years ago paved the way for people to pursue health options ranging from traditional Chinese medicines to manufactured vitamins with greater freedom. Caught up in the current were a number of cannabis-based therapies taking advantage of the growing attention paid to the plant’s medicinal properties. Pivot Pharmaceuticals Inc. (CSE:…

ThursdayMay 31, 2018 9:56 am

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Inks Option Agreement to Acquire Licensing Rights to TriVair™ Drug Delivery System

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it has signed an option agreement with IP Med Inc. to obtain an exclusive worldwide license for Trivair™ Nasal and Pulmonary Breath-Propelled Drug Delivery Systems™ for the delivery of Pivot's patented Ready-To-Infuse-Cannabis ("RTIC") cannabinoid products. The option expires in six months during which time Pivot will determine compatibility with its RTIC powder formulations and decide whether to enter into a definitive licensing agreement. "Pivot continues to grow its portfolio of patented technologies specifically for the formulation and delivery of cannabinoids. We are very excited about the unique…

WednesdayMay 30, 2018 9:50 am

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Inks Manufacturing Agreement with Bio V Pharma Inc.

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it has signed an exclusive contract manufacturing agreement with Bio V Pharma Inc. ("BioV"). Per the agreement, BioV, a Quebec-based full-service manufacturer of pharmaceutical and nutraceutical products, will manufacture, label, package and supply Pivot's entire bio-cannabis suite of products. In addition, Pivot has engaged Cannabis Compliance Inc. to apply to Health Canada for a Dealer's License under the Controlled Drugs and Substances Act and the Narcotic Control Regulations. A Dealer's License would enable the company to perform research and development, process natural health products, store cannabis derivatives,…

FridayMay 25, 2018 11:55 am

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Targeting Growing CBD Pet Market with New Product Line

Company’s new products are designed to address issues such as inflammation, joint pain, post-surgery pain and skin disorders in pets CBD pet market is heating up, with a growing number of cannabis companies already manufacturing products for this niche Pet owners spend more than $30 billion a year on supplements and other veterinary treatments, making CBD pet products a lucrative opportunity The multiple uses of cannabidiol (CBD) for domesticated animals, especially for dogs and cats, are gaining considerable attention from both consumers and the cannabis industry as a whole, with a growing number of cannabis companies tapping into this lucrative…

WednesdayMay 23, 2018 11:31 am

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Subsidiary Secures Manufacturing Facility in California

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that its wholly-owned U.S. subsidiary, Pivot Naturals LLC, ("PNL"), has entered a lease agreement for a manufacturing facility in Costa Mesa, California's Measure "X" Zone. PNL will immediately submit applications to acquire a Marijuana Business Permit, Conditional Use Permit and Business License. Businesses that meet the requirements to operate in Costa Mesa's Measure "X" Zone can establish research and development and testing laboratories and are permitted to conduct wholesale medical marijuana distributing, manufacturing, processing and transporting. The company intends to use the building as a state-of-the-art GMP manufacturing…

TuesdayMay 22, 2018 10:14 am

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) to Develop Additives and Formulations for Cannabis Beverage Market

Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it has initiated development of CBD and THC additives and formulations for the multi-billion dollar beverage industry using its patented Ready-To-Infuse-Cannabis (“RTIC”) Powder and Solmic Micelle water-soluble technologies. The program will be led by the company’s executive director of formulations, Dr. Leonid Lurya, at its contract lab in Israel. “Pivot will bring cannabis derivatives to market that are differentiated and backed by science. The beverage market opportunity is just too big to ignore and our patented technologies lend themselves well to this space,” Dr.…

FridayMay 18, 2018 10:07 am

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Fast-tracks Development for CBD Pet Product Line

Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that it has accelerated development of several cannabidiol ("CBD") products for the domestic pet food market. Pivot's pet product line will be marketed under the brand "Pivot Naturals For Pets" and will include capsules and sachets that deliver bio-available CBD to pets produced using the company’s patented Ready-To-Infuse-Cannabis powder as well as a line of pet creams developed using its Thrudermic Transdermal Nanotechnology. Pivot Naturals For Pets products will target indications such as joint pain, inflammation, post-surgical pain and skin disorders. "Pivot's technologies are versatile…

ThursdayMay 17, 2018 11:57 am

Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Cements Its Position in the Expanding Cannabis Industry

Global patents for innovative formulations and drug delivery platforms Strong development pipeline for cannabinoid-based pharmaceutical and nutraceutical products Capabilities to manufacture products of a quality unmatched by other industry players Canadian biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) continues to strengthen its position in the cannabis industry through the development of its patent-protected bio-cannabis products. The company’s current initiatives are geared toward the manufacture and commercialization of its product pipeline in anticipation of cannabis legalization in Canada, the United States and other regulated international markets. Pivot’s unique approach incorporates the acquisition of disruptive drug formulation and delivery…

ThursdayMay 17, 2018 10:23 am

QualityStocksNewsBreaks – Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) Subsidiary Enters Manufacturing and Supply Agreement in California

Vancouver-based biopharmaceutical company Pivot Pharmaceuticals Inc. (CSE: PVOT) (OTCQB: PVOTF) (FRA: NPAT) this morning announced that its wholly-owned California subsidiary, Pivot Naturals, LLC, has signed a definitive manufacturing and supply agreement with Stoney LLC, a leading brand of cannabis products in the state of California. Per the terms of the agreement, Stoney has agreed to purchase Pivot’s suite of Ready-To-Infuse-Cannabis (“RTIC”) powderized products, including formulated capsules for targeted effects, bulk powder for baking additives, single serve stick packs and pet food supplements. Order quantities will be determined in rolling 30-day periods commencing in 2018. “I am thrilled to execute our…

Site Search

Company Search

Tag: Pivot Pharmaceuticals Inc. PVOTF